Indian pharma industry to touch USD 130 billion by 2030: Dr Reddys Chief

Published On 2021-07-26 04:30 GMT   |   Update On 2021-07-26 08:20 GMT

Hyderabad: The Indian pharmaceutical industry is expected to grow almost by three times to about 130 billion US dollars by 2030, Chairman of Dr Reddy's Laboratories, K Satish Reddy said on Saturday. "If you see, currently it's (pharmaceutical industry) about 42 billion dollars, half between the domestic sales, half between the exports. We expect that it will grow almost by three times in...

Login or Register to read the full article

Hyderabad: The Indian pharmaceutical industry is expected to grow almost by three times to about 130 billion US dollars by 2030, Chairman of Dr Reddy's Laboratories, K Satish Reddy said on Saturday.

"If you see, currently it's (pharmaceutical industry) about 42 billion dollars, half between the domestic sales, half between the exports. We expect that it will grow almost by three times in the coming decade, reaching almost 120 to 130 billion dollars by 2030. Truly, we believe that we are poised for a tremendous growth in the coming decade," he predicted.

Reddy, Chairman of Board of Governors of NIPER- Hyderabad, was virtually addressing the 9th Convocation of the institute.

The government's encouragement (''Atma Nirbhar Bharat'' policy), a lot of reforms in the policy to incentivize the industry and thrust being given to innovation, among others, augur well for the industry, he said.

The Indian pharmaceutical industry worked continuously during the testing times of COVID-19 pandemic second wave to ensure the availability of life saving medicines.

During the period, the companies involved in making critical COVID-19 medicines responded very quickly ramping up production, he added.

He lauded the efforts of Union Chemicals and Fertilizers Minister Mansukh Mandaviya and the officials for providing a lot of interventions which helped the industry ramp up capacities.

Noting that the future of the Indian pharmaceutical industry is dependent on its ability to develop stronger capabilities in innovation and R&D, Reddy said such capabilities which already exist, need to be strengthened further.

The Indian pharmaceutical sector can contribute to the country through the development of drugs for India-specific ailments which, unfortunately, do not get much global attention, he rued.

He also said digital technologies were heralding a big change in the whole spectrum of healthcare - the way patients are treated, the way medicines are supplied to patients and automation in manufacturing.

A whole host of opportunities got accelerated during the pandemic, he added.

Secretary of the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, S Aparna spoke on efforts to attain self-sufficiency in APIs and others.

Read also: Dr Reddys says Sputnik V 2nd dose shortage to delay India's full rollout





Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News